Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Phase 3positiveLibtayoPositive

AI Analysis

Summary

Regeneron presented late-breaking Phase 3 C-POST data at ESMO 2026 demonstrating longer-term survival outcomes for Libtayo (cemiplimab) as adjuvant treatment in high-risk cutaneous squamous cell carcinoma following surgery and radiation.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo in high-risk CSCC

Importance:7/10

Sentiment:

0.70

oncologyPhase 3ESMOcutaneous squamous cell carcinomaLibtayosurvival datalate-breaking

Related Companies

$REGN

Read the original article

Published by GlobeNewswire Pharma on October 6, 2026 11:00 AM

Read Original